132 related articles for article (PubMed ID: 36423860)
1. Multi-targeting TACE/ADAM17 and gamma-secretase of notch signalling pathway in TNBC via drug repurposing approach using Lomitapide.
Sen P; Kandasamy T; Ghosh SS
Cell Signal; 2023 Feb; 102():110529. PubMed ID: 36423860
[TBL] [Abstract][Full Text] [Related]
2. A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling.
Das A; Narayanam MK; Paul S; Mukhnerjee P; Ghosh S; Dastidar DG; Chakrabarty S; Ganguli A; Basu B; Pal M; Chatterji U; Banerjee SK; Karmakar P; Kumar D; Chakrabarti G
J Biol Chem; 2019 Apr; 294(17):6733-6750. PubMed ID: 30824542
[TBL] [Abstract][Full Text] [Related]
3. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
[TBL] [Abstract][Full Text] [Related]
4. Honokiol inhibits melanoma stem cells by targeting notch signaling.
Kaushik G; Venugopal A; Ramamoorthy P; Standing D; Subramaniam D; Umar S; Jensen RA; Anant S; Mammen JM
Mol Carcinog; 2015 Dec; 54(12):1710-21. PubMed ID: 25491779
[TBL] [Abstract][Full Text] [Related]
5. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
6. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
Shome R; Ghosh SS
ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
[TBL] [Abstract][Full Text] [Related]
7. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
8. Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer.
Hossain F; Ucar DA; Monticone G; Ran Y; Majumder S; Larter K; Luu H; Wyczechowska D; Heidari S; Xu K; Shanthalingam S; Matossian M; Xi Y; Burow M; Collins-Burow B; Del Valle L; Hicks C; Zabaleta J; Golde T; Osborne B; Miele L
Front Immunol; 2023; 14():1244159. PubMed ID: 37901240
[TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
[TBL] [Abstract][Full Text] [Related]
10. Bulbine frutescens phytochemical inhibits notch signaling pathway and induces apoptosis in triple negative and luminal breast cancer cells.
Kushwaha PP; Vardhan PS; Kapewangolo P; Shuaib M; Prajapati SK; Singh AK; Kumar S
Life Sci; 2019 Oct; 234():116783. PubMed ID: 31442552
[TBL] [Abstract][Full Text] [Related]
11. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
12. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ADAM-17 more effectively down-regulates the Notch pathway than that of γ-secretase in renal carcinoma.
Guo Z; Jin X; Jia H
J Exp Clin Cancer Res; 2013 May; 32(1):26. PubMed ID: 23659326
[TBL] [Abstract][Full Text] [Related]
14. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK
Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372
[TBL] [Abstract][Full Text] [Related]
15. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
[TBL] [Abstract][Full Text] [Related]
16. Cimigenoside functions as a novel γ-secretase inhibitor and inhibits the proliferation or metastasis of human breast cancer cells by γ-secretase/Notch axis.
Jia H; Liu M; Wang X; Jiang Q; Wang S; Santhanam RK; Lv C; Zhao Q; Lu J
Pharmacol Res; 2021 Jul; 169():105686. PubMed ID: 34022397
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance.
Feng M; Santhanam RK; Xing H; Zhou M; Jia H
Biochem Pharmacol; 2024 Feb; 220():115991. PubMed ID: 38135129
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
[TBL] [Abstract][Full Text] [Related]
19. Phenylboronic acid modified lipid nanocarriers mediated co-delivery of immunocytokine TRAIL and gamma-secretase inhibitor to triple negative breast cancer cells and cancer stem cells.
Pindiprolu SKSS; Avasarala H; Dinakaran SK
Med Hypotheses; 2021 Dec; 157():110716. PubMed ID: 34731681
[TBL] [Abstract][Full Text] [Related]
20. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]